Contrast-Enhancement of the Anterior Eye Segment in Patients with Retinoblastoma: Correlation between Clinical, MR Imaging, and Histopathologic Findings

References

1. 1.↵
   1. Lumbroso-Le Rouic L,
   2. Aerts I,
   3. Levy-Gabriel C,
   4. et al

   . Conservative treatments of intraocular retinoblastoma. Ophthalmology 2008;115:1405–10

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Chantada GL,
   2. Dunkel IJ,
   3. Antoneli CB,
   4. et al

   . Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer 2007;49:256–60

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Chantada GL,
   2. Casco F,
   3. Fandino AC,
   4. et al

   . Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007;114:2083–89

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Uusitalo MS,
   2. Van Quill KR,
   3. Scott IU,
   4. et al

   . Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001;119:41–48

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Schueler AO,
   2. Hosten N,
   3. Bechrakis NE,
   4. et al

   . High resolution magnetic resonance imaging of retinoblastoma. Br J Ophthalmol 2003;87:330–35

   Abstract/FREE Full Text
6. 6.↵
   1. de Graaf P,
   2. Barkhof F,
   3. Moll AC,
   4. et al

   . Retinoblastoma: MR imaging parameters in detection of tumor extent. Radiology 2005;235:197–207

   CrossRefPubMed
7. 7.↵
   1. Lemke AJ,
   2. Kazi I,
   3. Mergner U,
   4. et al

   . Retinoblastoma: MR appearance using a surface coil in comparison with histopathological results. Eur Radiol 2007;17:49–60

   CrossRefPubMed
8. 8.↵
   1. Brisse HJ,
   2. Guesmi M,
   3. Aerts I,
   4. et al

   . Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison. Pediatr Radiol 2007;37:649–56

   CrossRefPubMed
9. 9.↵
   1. Marback EF,
   2. Arias VE,
   3. Paranhos A Jr.,
   4. et al

   . Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol 2003;87:1224–28

   Abstract/FREE Full Text
10. 10.↵
    1. Rossler J,
    2. Dietrich T,
    3. Pavlakovic H,
    4. et al

    . Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol 2004;164:391–94

    PubMedWeb of Science
11. 11.↵
    1. Jockovich ME,
    2. Suarez F,
    3. Alegret A,
    4. et al

    . Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Invest Ophthalmol Vis Sci 2007;48:5371–76

    Abstract/FREE Full Text
12. 12.↵
    1. Pe'er J,
    2. Neufeld M,
    3. Baras M,
    4. et al

    . Rubeosis iridis in retinoblastoma: histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology 1997;104:1251–58

    PubMedWeb of Science
13. 13.↵
    1. Kvanta A,
    2. Steen B,
    3. Seregard S

    . Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 1996;63:511–18

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Stitt AW,
    2. Simpson DA,
    3. Boocock C,
    4. et al

    . Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998;186:306–12

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Kuchle M,
    2. Vinores SA,
    3. Green WR

    . Immunohistochemical evaluation of the integrity of the blood-aqueous barrier in normal and rubeotic human eyes. Graefes Arch Clin Exp Ophthalmol 1995;233:414–20

    CrossRefPubMed
16. 16.↵
    1. Miller JW,
    2. Adamis AP,
    3. Shima DT,
    4. et al

    . Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574–84

    PubMedWeb of Science
17. 17.↵
    1. Tolentino MJ,
    2. Miller JW,
    3. Gragoudas ES,
    4. et al

    . Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964–70

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Galluzzi P,
    2. Cerase A,
    3. Hadjistilianou T,
    4. et al

    . Retinoblastoma: abnormal gadolinium enhancement of anterior segment of eyes at MR imaging with clinical and histopathologic correlation. Radiology 2003;228:683–90. Epub 2003 Jul 24

    CrossRefPubMed
19. 19.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74

    CrossRefPubMedWeb of Science
20. 20.
    1. Freddo TF

    . Shifting the paradigm of the blood-aqueous barrier. Exp Eye Res 2001;73:581–92

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Bert RJ,
    2. Caruthers SD,
    3. Jara H,
    4. et al

    . Demonstration of an anterior diffusional pathway for solutes in the normal human eye with high spatial resolution contrast-enhanced dynamic MR imaging. Invest Ophthalmol Vis Sci 2006;47:5153–62

    Abstract/FREE Full Text
22. 22.↵
    1. Bert R,
    2. Freddo T,
    3. Caruthers SD,
    4. et al

    . Confirmation of an anterior large-molecule diffusion pathway in the normal human eye. Invest Ophthalmol Vis Sci 1999;40(suppl):S198
23. 23.↵
    1. Chen CJ

    . Intraocular contrast enhancement in Adams pattern III hypoxic brain damage: MRI. Neuroradiology 2000;42:54–55

    CrossRefPubMed
24. 24.↵
    1. Kerbel R,
    2. Folkman J

    . Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–39

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Penn JS,
    2. Madan A,
    3. Caldwell RB,
    4. et al

    . Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008;27:331–71

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Ferrara N

    . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Vermeulen PB,
    2. Gasparini G,
    3. Fox SB,
    4. et al

    . Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564–79

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Ino-ue M,
    2. Azumi A,
    3. Shirabe H,
    4. et al

    . Iridopathy in eyes with proliferative diabetic retinopathy: detection of early stage of rubeosis iridis. Ophthalmologica 1998;212:15–18

    CrossRefPubMed
29. 29.↵
    1. Imhof BA,
    2. Aurrand-Lions M

    . Angiogenesis and inflammation face off. Nat Med 2006;12:171–72

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Matsubayashi R,
    2. Matsuo Y,
    3. Edakuni G,
    4. et al

    . Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000;217:841–48

    PubMedWeb of Science
31. 31.↵
    1. Teraoka H,
    2. Sawada T,
    3. Nishihara T,
    4. et al

    . Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 2001;85:612–17

    CrossRefPubMed
32. 32.↵
    1. Brancato R,
    2. Bandello F,
    3. Lattanzio R

    . Iris fluorescein angiography in clinical practice. Surv Ophthalmol 1997;42:41–70

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Rebeles F,
    2. Fink J,
    3. Anzai Y,
    4. et al

    . Blood-brain barrier imaging and therapeutic potentials. Top Magn Reson Imaging 2006;17:107–16

    CrossRefPubMed
34. 34.↵
    1. Jubb AM,
    2. Oates AJ,
    3. Holden S,
    4. et al

    . Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626–35

    CrossRefPubMedWeb of Science